The craft of prolog /

Por OþKeefe, Richard A.
Publicado em 1990

Should cognitive impairment be included in the diagnostic criteria for schizophrenia?

Por KEEFE, RICHARD S.E.
Publicado em 2008

Missing the Sweet Spot Disengagement in Schizophrenia

Por Keefe, Richard S.E.
Publicado em 2006

Guide to assessment scales in schizophrenia

Por Keefe, Richard, Addington, Jean
Publicado em c201

How Should DSM-V Criteria for Schizophrenia Include Cognitive Impairment?

Por Keefe, Richard S. E., Fenton, Wayne S.
Publicado em 2007

Implementation Considerations for Multisite Clinical Trials with Cognitive Neuroscience Tasks

Por Keefe, Richard S. E., Harvey, Philip D.
Publicado em 2008

Technology, Society, and Mental Illness: Challenges and Opportunities for Assessment and Treatment

Por Harvey, Philip D., SE Keefe, Richard
Publicado em 2012

Cognition and Schizophrenia: Is There a Role for Cognitive Assessments in Diagnosis and Treatment?

Por Targum, Steven D, Keefe, Richard S.E.
Publicado em 2008

Anticipating DSM-V: Opportunities and Challenges for Cognition and Psychosis

Por Barch, Deanna M., Keefe, Richard S.E.
Publicado em 2010

Failures in Learning-Dependent Predictive Perception as the Key Cognitive Vulnerability to Psychosis in Schizophrenia

Por Keefe, Richard S E, Kraus, Michael S, Krishnan, Ranga R
Publicado em 2011

43. Cognitive Functioning in First-Episode Psychosis:_x000B_ Comparison of a 2-Year Coordinated Specialty Care Program to Community Care

Por Schooler, Nina, Khan, Anzalee, Keefe, Richard, Robinson, Delbert, Kane, John
Publicado no Schizophr Bull (2017)

A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder

Por Mahableshwarkar, Atul R, Zajecka, John, Jacobson, William, Chen, Yinzhong, Keefe, Richard SE
Publicado no Neuropsychopharmacology (2015)

A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder

Por Mahableshwarkar, Atul R, Zajecka, John, Jacobson, William, Chen, Yinzhong, Keefe, Richard SE
Publicado no Neuropsychopharmacology (2016)

Use of Antipsychotics Pre- and Post-Dissemination of CATIE Data

Por Cascade, Elisa F., Kalali, Amir H., Lieberman, Jeffrey, Hsiao, John, Keefe, Richard, Stroup, Scott
Publicado em 2007

Circumstances Under Which Practice Does Not Make Perfect: A Review of the Practice Effect Literature in Schizophrenia and Its Relevance to Clinical Treatment Studies

Por Goldberg, Terry E, Keefe, Richard S E, Goldman, Robert S, Robinson, Delbert G, Harvey, Philip D
Publicado em 2010

Methodological Issues in Negative Symptom Trials

Por Marder, Stephen R., Daniel, David G., Alphs, Larry, Awad, A. George, Keefe, Richard S. E.
Publicado em 2011

Abbreviated neuropsychological assessment in schizophrenia: Prediction of different aspects of outcome

Por Harvey, Philip D., Keefe, Richard S. E., Patterson, Thomas L., Heaton, Robert K., Bowie, Christopher R.
Publicado em 2009

A Brief Cognitive Assessment Tool for Schizophrenia: Construction of a Tool for Clinicians

Por Hurford, Irene M., Marder, Stephen R., Keefe, Richard S. E., Reise, Steven P., Bilder, Robert M.
Publicado em 2011

Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsy...

Por Lipkovich, Ilya A, Deberdt, Walter, Csernansky, John G, Sabbe, Bernard, Keefe, Richard SE, Kollack-Walker, Sara
Publicado em 2009

The FDA-NIMH-MATRICS Guidelines for Clinical Trial Design of Cognitive-Enhancing Drugs: What Do We Know 5 Years Later?

Por Buchanan, Robert W., Keefe, Richard S. E., Umbricht, Daniel, Green, Michael F., Laughren, Thomas, Marder, Stephen R.
Publicado em 2011